Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays

By Yahoo! Finance | Sep 19, 2024 at 12:48 PM EST

Theratechnologies Inc. faces a possible supply disruption for Egrifta SV due to the contract manufacturer's facility shutdown after an FDA inspection. The company is working to minimize patient impact and anticipates a revenue shortfall of $1.6 million in fiscal year 2024.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.